1,474
Views
26
CrossRef citations to date
0
Altmetric
Original Articles

Effect of functionalization on drug delivery potential of carbon nanotubes

, , &
Pages 1851-1860 | Received 30 Jul 2015, Accepted 13 Oct 2015, Published online: 06 Jan 2016

Figures & data

Scheme 1. Preparation of N-Hydroxy succinimide (NHS) ester of folic acid.

Scheme 1. Preparation of N-Hydroxy succinimide (NHS) ester of folic acid.

Scheme 2. Conjugation of FA with PEG-bis-amine 3000.

Scheme 2. Conjugation of FA with PEG-bis-amine 3000.

Figure 1. The FTIR spectrum of acid-treated MWCNTs.

Figure 1. The FTIR spectrum of acid-treated MWCNTs.

Figure 2. The FTIR spectrum of DOX/PEG-FA-MWCNTs conjugate.

Figure 2. The FTIR spectrum of DOX/PEG-FA-MWCNTs conjugate.

Table I. The characteristic peaks interpretation of functionalized MWCNTs.

Table II. The particle size of MWCNTs after purification.

Figure 3. Dispersion analysis of MWCNTs in different surfactants (Triton X-100, Tween-80 and sodium lauryl sulfate).

Figure 3. Dispersion analysis of MWCNTs in different surfactants (Triton X-100, Tween-80 and sodium lauryl sulfate).

Table III. The dispersion of MWCNTs in different surfactants.

Figure 4. SEM images of DOX/PEG-FA- MWCNTs shown at 50,000 × and 30,000 × magnification.

Figure 4. SEM images of DOX/PEG-FA- MWCNTs shown at 50,000 × and 30,000 × magnification.

Figure 5. Motic image of DOX-loaded functionalized MWCNTs.

Figure 5. Motic image of DOX-loaded functionalized MWCNTs.

Figure 6. Cumulative percent drug release from various MWCNTs nanoformulations.

Figure 6. Cumulative percent drug release from various MWCNTs nanoformulations.

Figure 7. Percent cell viability of MCF-7 cell after treated with free DOX, DOX/MWCNTs, DOX/PEG-MWCNTs and DOX/PEG-FA-MWCNTs.

Figure 7. Percent cell viability of MCF-7 cell after treated with free DOX, DOX/MWCNTs, DOX/PEG-MWCNTs and DOX/PEG-FA-MWCNTs.

Figure 8. Cellular uptake of doxorubicin in MCF-7 cell lines.

Figure 8. Cellular uptake of doxorubicin in MCF-7 cell lines.

Table IV. The various pharmacokinetic parameters.

Figure 9. Biodistribution study of MWCNTs nanoformulations in different organs.

Figure 9. Biodistribution study of MWCNTs nanoformulations in different organs.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.